Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSDI Group Regulatory News (SDI)

Share Price Information for SDI Group (SDI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 54.50
Bid: 54.00
Ask: 55.00
Change: -1.60 (-2.88%)
Spread: 1.00 (1.852%)
Open: 55.50
High: 56.00
Low: 54.00
Prev. Close: 55.60
SDI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

7 Dec 2022 07:00

RNS Number : 8145I
SDI Group PLC
07 December 2022
 

 

 

SDI Group plc

 

("SDI", "SDI Group", the "Company", or the "Group")

 

Interim results for the six months ended 31 October 2022

 

SDI Group plc, the AIM quoted Group focused on the design and manufacture of scientific and technology products for use in digital imaging and sensing and control applications, is pleased to announce another strong set of results and solid operational progress for the six months to the end of October 2022.

 

 

Financial Highlights

 

· Revenue increased by 28.3% to £31.7m (H1 FY22: £24.7m)

· Adjusted operating profit* for the period increased by 19.0% to £6.9m (H1 FY22: £5.8m)

Reported operating profit increased by 7.7% to £5.6m (H1 FY22: £5.2m)

· Adjusted profit before tax* increased by 14.0% to £6.5m (H1 FY22: £5.7m)

Reported profit before tax increased by 3.9% to £5.3m (H1 FY22: £5.1m)

· Adjusted diluted EPS* increased by 28.1% to 5.02p (H1 FY22: 3.92p)

Reported diluted EPS increased by 18.4% to 4.06p (H1 FY22: 3.43p)

 

Operational Highlights

 

· Two new acquisitions added to the Group - LTE Scientific Limited and Fraser Anti-Static Techniques Limited

 

· Growth over the first half of FY23, including 3.8% organic growth and 24.5% from acquisitions

 

Ken Ford, Chairman of SDI Group, said:

 

"We are pleased to report yet another strong set of financial results. SDI Group continues to execute on its business model, adding two quality businesses to our portfolio and maintaining growth. A higher interest rate environment will lead to a small increase in interest rate expense in the second half. We look forward to delivering a full year trading performance in line with market expectations."

 

*before acquisition costs, share based payments, reorganisation costs and amortisation of acquired intangible assets.

 

Analysts from our Broker finnCap Limited and from Progressive Equity Research regularly provide research on the Company, and the Group considers the average of their forecasts to represent market expectations for FY23 being Sales of £66.3m and Adjusted Operating Profit of £12.80m

 

Enquiries

 

SDI Group plc 01223 727144

Ken Ford, Chairman

Mike Creedon, CEO

Ami Sharma, CFO

www.sdigroup.com

 

finnCap Ltd 020 7220 0500

Ed Frisby/Seamus Fricker/Milesh Hindocha - Corporate Finance

Andrew Burdis/Sunila de Silva - ECM

SDl Group plc is an AIM quoted company specialising in the design and manufacture of products for use within a number of imaging and sensing and control applications including life sciences, healthcare, plastics and packaging, astronomy, precision optics, measurement instrumentation and art conservation markets.

Corporate expansion is via organic growth within its subsidiary companies and through the acquisition of complementary, niche technology businesses with established reputations in global markets.

No statement in this announcement is intended to be a profit forecast or estimate and no statement in this announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.

Chairman's statement

 

As the coronavirus pandemic partly recedes into the rear-view mirror, we emerge into a different more uncertain world, with high inflation and the UK economy fast approaching a recession, if it is not there already. In this sort of environment, our agile business model, which involves smaller niche autonomous businesses operating in a multitude of markets gives us the ability to respond quickly to market movements. We are still delivering products at volume that are being used in the Covid detection effort but, as previously communicated, it is expected that this will reduce over the second half of the year. However, our businesses have room to grow in their markets and we expect that to continue.

 

We acquired two new businesses in the first half of the financial year in line with our growth strategy. This brings the total number of businesses acquired over the calendar year to four. LTE Scientific Limited ("LTE") was acquired in July and Fraser Anti-Static Techniques Limited ("Fraser") in October. LTE is a UK company which specialises in the design, manufacture and servicing of sterilizers, decontamination and thermal processing equipment, used in the life science and medical market sectors. Fraser is a leading UK manufacturer of anti-static products which eliminate, clean, generate or measure static electricity in a variety of industries including plastics, packaging and printing, amongst others. Fraser's technologies and markets are unrelated to our current portfolio. However, LTE operates in a market with which we are already familiar. Both companies fit perfectly within our acquisition criteria and have become part of our Sensors and Control segment. These businesses will be operated separately from our existing businesses. We warmly welcome our new colleagues to the SDI Group.

 

Board

 

As previously communicated, Ami Sharma took over as CFO in August from Jon Abell who retired in September after a handover period.

 

In August, Andrew Hosty was appointed to the Board as a non-executive director as Isabel Napper stepped down. The Board intends to appoint another non-executive director in due course.

 

Trading

 

Demand from OEM customers was more variable this half year than the equivalent period last year. A strong market for chiller products and cameras was offset to some degree by continuing subdued demand for capital equipment purchases for general laboratory use. Positively, the easing of pandemic rules has made servicing activity easier to arrange and carry out. In common with manufacturing industry across the world, and perhaps especially in the UK, the pandemic is causing supply chain issues to all our businesses. These continue to be a significant drain on management time, and our businesses are having to work hard to source components or modify designs for missing ones. This is expected to continue. It has impacted upon the timing of deliveries for some of our businesses.

 

Inflationary cost increases have, in general, been passed on to customers where possible and gross margins have generally held.

 

The good news is that the general level of sales enquiries remains at a strong level. Prior to the pandemic, trade fairs and exhibitions provided a robust avenue for generating sales leads and meeting OEMs. It is pleasing to report that in-person trade fairs and exhibitions have re-started and several of our businesses have attended them, with positive feedback received. Examples include ACHEMA (Berlin), Analytica (Frankfurt) and VISION (Stuttgart). Direct face to face meetings with customers, an effective method of launching new products, have become more common as business life starts to return to some level of normality.

 

The addition of LTE to the Group adds to our existing businesses, Monmouth, Safelab Systems and Synoptics, which sell into the laboratory market and provides an opportunity for synergies. The Group will maintain the identity and autonomy of these companies in their current locations, but the businesses are actively seeking and finding areas of co-operation to reduce costs and enhance their total customer offer.

 

Revenues

 

Group revenues increased by 28.3% to £31.7m (H1 FY22: £24.7m). The increase was driven by two major factors:

 

· Our Atik Cameras business has continued to increase revenues year on year. This has been driven by sales of cameras to an international OEM for use in PCR machines as well as increased general demand for other types of cameras. We expect current orders, paid for in advance of shipment, to be fulfilled over the second half of the financial year, and we have no visibility of further orders from the international OEM customer. The business has, however, experienced strong organic growth when excluding this contract.

 

· Acquisitions over the second half of FY22 and the first half of FY23, SVS, Safelab Systems and LTE, delivered £6.1m of sales. Both SVS and Safelab Systems are ahead of expectations, with LTE being acquired recently. Fraser was acquired at the very end of H1 FY23.

 

Organic revenue growth across the business was 3.8%. The three-year pandemic period from FY20 to FY22 produced revenue and profit fluctuations which have not fully settled yet, but H1 FY23 has stronger comparatives than H1 FY22. As noted above Atik Cameras continue to deliver on their large PCR camera order, whilst strong demand for scientific and industrial cooling systems drove growth at Applied Thermal. This was offset by a softer post COVID market for both Monmouth Scientific and Synoptics, particularly in the UK. Component delays have impacted upon Astles Control Systems and Chell Instruments delivery timings, but Sentek experienced strong demand for chemical sensors.

 

Sales in our Digital Imaging segment grew by 9.6% to £12.5m (H1 FY22: £11.4m) and sales in Sensors & Control were 44.4% higher at £19.2m (H1 FY22: £13.3m), the latter all acquisition driven.

 

Profits

 

Gross margins were lower than in H1 FY22, due to mix, with the acquisitions having slightly lower gross margins than the Group average. We have increased prices to offset the impacts of component and raw material price increases, and generally we have seen customer acceptance of this.

 

Overheads are higher than the comparative period mainly due to acquisitions, inflation, both for salaries and other overheads and some organic headcount increases. Most of our power and heat costs are fixed until Q1 2023.

 

Adjusted Group profit before tax increased by 14.0% to £6.5m (H1 FY22: £5.7m). Statutory Group profit before tax increased by 3.9% to £5.3m (H1 FY22: £5.1m) driven by the organic revenue growth and the contribution of the H2 FY22 acquired businesses.

 

In addition to the performance measures defined under IFRS, the Group also provides adjusted results in which certain one-time and non-cash charges are excluded, to help shareholders understand the underlying operating performance. Adjustments for the period were for the amortisation of acquired intangible assets, share-based payments and acquisition costs totalling £1.2m (H1 FY22: £0.6m).

 

Our effective tax rate (on adjusted profit before tax) was 16.2% (H1 FY22: 26.7%). The prior period effective tax rate was higher as it included an adjustment of £0.6m to align certain deferred tax assets and liabilities (except for deferred tax assets related to share options) to the new UK corporate tax rate of 25.0% from April 2023.

 

A £0.2m favourable impact from aligning the deferred tax asset for future share option gains to current share prices and tax rates has been booked directly to equity.

 

Basic earnings per share increased by 15.0% to 4.15p (H1 FY22: 3.61p); diluted earnings per share increased by 18.4% to 4.06p (H1 FY22: 3.43p). Adjusted diluted earnings per share increased by 28.1% to 5.02p (H1 FY22: 3.92p).

 

Cash flow

 

Cash generated from operations reduced to £1.9m (H1 FY22: £4.4m). The reduction was due to a £2m build-up of inventories to mitigate the impact of component shortages and PCR camera deliveries due to be shipped over the second half of the year and a £1.3m reduction in customer advances, largely due to PCR camera shipments in the first half.

 

The Group acquired two businesses over the period (see below). A total of £20.9m in cash was paid offset by a net £6.7m of cash acquired with the two businesses. In June 2022 we paid the deferred consideration of £2.4m for the prior year acquisition of Safelab Systems Limited. A further £1.0m in deferred consideration relating to the acquisition of Scientific Vacuum Systems Limited remains outstanding pending assessment of the earn-out conditions and is accrued in trade and other payables.

 

Net debt, or bank debt less cash, was £15.4m at 31 October 2022, compared to a net cash position at 30 April 2022 and 31 October 2021 of £1.1m at both dates. This represents a net debt: EBITDA ratio of 1.0x, which compares to a 2.5x ceiling provided by our bank facility. At 31 October 2022, the Group had £1m of headroom within its £20m committed loan facility with HSBC. On 30 November 2022, the Group reached agreement with HSBC to exercise £5m of an available £10m accordion option, which increased the committed loan facility from £20m to £25m, hence increasing the available head room to £6m. The balance of the accordion option (£5m) remains available to the Group (at the discretion of HSBC) for future exercise. The Group has an unstretched balance sheet and has sufficient access to funds, alongside its steady cash flow, to acquire new companies and invest in our current portfolio of businesses.

 

Operations

 

Whilst staff turnover generally remains low, we continue to experience a tight labour market. We have managed to fill some, but not all, skilled vacancies relatively quickly. Cost increases, in relation to materials, have generally been passed on to customers.

 

Our rolling programme of upgrading manufacturing facilities across the Group continues with the refurbishment of the Graticules Optics factory in Tonbridge. This investment will bring a capacity increase as well as improving efficiency, staff comfort, product quality and image.

 

We continue to invest in expanding and enhancing our product range. The hiring of some new marketing talent has also resulted in some improved website designs with positive results to date.

 

Acquisitions

 

On 29 July 2022, the Group acquired 100% of the share capital of LTE for a total consideration of £5.5m, which included freehold ownership of its manufacturing facility, valued at approximately £1.7m. On the date of the acquisition, LTE had £2.6m of cash in hand.

 

LTE specialises in the design, manufacture and servicing of sterilizers, decontamination and thermal processing equipment, used in the life science and medical market sectors. Other manufactured products include environmental rooms and chambers, endoscope storage cabinets, laboratory ovens, incubators and drying cabinets. LTE operates in similar markets to Monmouth Scientific and Safelab Systems, albeit with different products, and is based in Greenfield, Greater Manchester.

 

On 21 October 2022, the Group acquired 100% of the share capital of Fraser Anti-Static Techniques Limited ("Fraser"), for a total consideration of £16.9m, of which £15.4m was paid before the period end and £1.5m (accrued in other payables) is due to be paid over the second half of the financial year. Approximately £1.0m of the deferred consideration is based on net assets on completion date. The total consideration includes freehold ownership of three of Fraser's manufacturing sites, valued at approximately £1.8m, and the business had approximately £4.1m of cash in hand on the date of completion.

Fraser is a leading UK manufacturer of anti-static products which eliminate, clean, generate or measure static electricity in a variety of industries including plastics, packaging, printing, food processing, medical and pharma amongst others. The business has sites in Bampton, Devon and Bristol as well as sales offices in Shanghai, China and Dresden, Germany. Fraser's markets are mainly global, and the business is considered to be one of the top ten suppliers of anti-static products.

Outlook

 

The COVID 19 related orders at Atik will complete this financial year, as has been previously communicated. The weighting of these camera deliveries are skewed to the first half of the year. SDI Group continues to execute on its business model, adding two quality businesses to our portfolio and maintaining growth. A higher interest rate environment will lead to a small increase in interest rate expense in the second half. We look forward to delivering a full year trading performance in line with market expectations.

 

 

 

 

 

 

Ken Ford, Chairman

7 December 2022

Consolidated income statement

Unaudited for the six months ended 31 October 2022

 

 

 

 

 

 

 

Note

 

6 months to

31 October

2022

Unaudited

£'000

6 months to

31 October

2021

Unaudited

£'000

12 months to

30 April

2022

Audited

£'000

Revenue

 

31,720

24,655

 

49,656

Costs of sales

 

(11,764)

(8,783)

 

(17,998)

Gross Profit

 

19,956

15,882

 

31,658

 

 

 

 

 

Other operating income

50

20

 

55

Operating expenses

(14,383)

(10,695)

 

(21,534)

Operating profit

 

5,623

5,207

 

10,179

Net financing expense

 

(318)

(105)

 

(295)

Profit before taxation

 

5,305

5,102

 

9,884

Income tax charge

8

 

(1,061)

(1,526)

 

(2,341)

Profit for the period

 

4,244

3,576

 

7,543

Earnings per share

5

 

 

 

 

Basic earnings per share

 

4.15p

3.61p

 

7.53p

Diluted earnings per share

 

4.06p

3.43p

 

7.23p

 

 

 

Consolidated statement of comprehensive income

Unaudited for the six months ended 31 October 2022

 

 

6 months to

31 October

2022

Unaudited

£'000

6 months to

31 October

2021

Unaudited

£'000

12 months to

30 April

2022

Audited

£'000

Profit for the period

 

4,244

3,576

7,543

Other comprehensive income

 

 

 

Exchange differences on translating foreign operations

 

 

170

 

(161)

 

46

Total comprehensive profit for the period

 

 

4,414

 

3,415

 

7,497

 

Consolidated balance sheet

Unaudited at 31 October 2022

 

Note

31 October

2022

Unaudited

£'000

31 October

2021

Unaudited

£'000

30 April

2022

Audited

£'000

Assets

 

Non-current assets

 

Intangible assets

47,264

25,730

36,035

Property, plant and equipment

15,015

4,225

11,379

Deferred tax asset

8

1,547

1,660

1,586

63,826

31,615

49,000

Current assets

 

Inventories

12,066

6,957

7,273

Trade and other receivables

11,566

7,786

7,544

Cash and cash equivalents

3,619

3,513

5,106

27,251

18,256

19,923

Total assets

91,077

49,871

68,923

Liabilities

 

 

Non-current liabilities

 

 

Borrowings

6

19,000

1,029

4,000

Lease liabilities

6

6,304

1,936

6,656

Deferred tax liability

8

5,795

2,993

4,417

31,099

5,958

15,073

Current liabilities

 

 

Trade and other payables

16,543

9,727

16,089

Provisions

88

230

163

Borrowings

6

-

1,371

-

Lease liabilities

6

802

498

779

Current tax payable

1,889

1,165

1,027

19,322

12,991

18,058

Total liabilities

50,421

18,949

33,131

Net assets

40,656

30,922

35,792

Equity

 

 

Share capital

1,027

996

1,022

Merger reserve

2,606

2,606

2,606

Merger relief reserve

424

424

424

Share premium account

10,093

9,359

9,905

Share-based payment reserve

656

728

320

Foreign exchange reserve

209

(76)

39

Retained earnings

25,641

16,885

21,476

Total equity

40,656

30,922

35,792

 

Consolidated statement of cash flows

Unaudited for the six months ended 31 October 2022

 

Note

6 months to

31 October

2022

Unaudited

£'000

6 months to

31 October

2021

Unaudited

£'000

12 months to

30 April

2022

Audited

£'000

Operating activities

 

 

 

Net profit for the period

 

4,244

3,577

7,543

Depreciation and amortisation

 

2,010

1,315

2,773

Finance costs and income

 

318

105

295

Impairment of intangibles

 

-

-

30

Changes in provisions

 

(75)

-

(97)

Taxation expense in the income statement

 

1,061

1,526

2,341

Employee share-based payments

 

140

159

313

Operating cash flow before movement in working capital

 

 

7,698

 

6,682

13,198

 

 

Changes in inventories

 

(1,906)

(886)

(365)

Changes in trade and other receivables

 

(1,070)

(573)

652

Changes in trade and other payables

 

(2,847)

(808)

1,204

Cash generated from operations

 

1,875

4,415

14,689

 

 

Interest paid

 

(318)

(105)

(295)

Income taxes paid

 

(691)

(735)

(1,290)

Cash generated from operating activities

 

866

3,575

13,104

 

 

 

Cash flows from investing activities

 

 

Capital expenditure on fixed assets

 

(443)

(510)

(1,426)

Sale of property plant and equipment

 

10

32

66

Expenditure on development and other intangibles

 

(183)

(115)

(415)

Acquisition of subsidiaries, net of cash

7

(16,523)

(2,500)

(10,995)

Net cash used in investing activities

 

(17,139)

(3,093)

(12,770)

 

 

 

Cash flows from financing activities

 

 

Payments of lease liabilities

 

(386)

(296)

(583)

Proceeds from bank borrowings

 

15,000

-

9,000

Repayment of borrowings

 

-

(686)

(8,086)

Issues of shares & proceeds from option exercises

 

-

278

651

Net cash from/(used in) financing activities

 

14,614

(704)

982

 

 

 

Net (decrease)/increase in cash and cash equivalents

 

 

(1,659)

 

(222)

1,316

 

 

 

Cash and cash equivalents, beginning of period

 

5,106

3,836

3,836

Foreign currency movements on cash balances

 

172

(101)

(46)

Cash and cash equivalents, end of period

 

3,619

3,513

5,106

Consolidated statement of changes in equity

Unaudited for the six months ended 31 October 2022

 

6 months to 31 October 2022 - unaudited

Share

capital

£'000

Merger

reserve

£'000

 

Merger relief reserve

£'000

Foreign

exchange

£'000

Share

premium

£'000

Share-based payment reserve

£'000

Retained

earnings

£'000

 

Total

£'000

Balance at 1 May 2022

1,022

2,606

424

39

9,905

320

21,476

35,792

Shares issued

5

-

-

-

188

-

-

193

Tax in respect to share options

-

-

-

-

-

-

117

117

Share-based payments transfer

-

-

-

-

-

196

(196)

-

Share based payments

-

-

-

-

-

140

-

140

Transactions with owners

5

-

-

-

188

336

(79)

450

Profit for the period

-

-

-

-

-

-

4,244

4,244

Foreign exchange on consolidation of subsidiaries

 

-

 

-

 

-

 

170

 

-

 

-

 

-

 

170

Total comprehensive income for the period

 

-

 

-

 

-

 

170

 

-

 

-

 

4,244

 

4,414

Balance at 31 October 2022

1,027

2,606

424

209

10,093

656

25,641

40,656

 

 

6 months to 31 October 2021 - unaudited

Share

capital

£'000

Merger

reserve

£'000

 

Merger relief reserve

£'000

Foreign

exchange

£'000

Share

premium

£'000

Share-based payment reserve

£'000

Retained

earnings

£'000

 

Total

£'000

Balance at 1 May 2021

984

2,606

424

85

9,092

714

12,869

26,774

Shares issued

12

-

-

-

267

-

-

279

Tax in respect to share options

-

-

-

-

-

-

295

295

Share-based payments transfer

-

-

-

-

-

(145)

145

-

Share based payments

-

-

-

-

-

159

-

159

Transactions with owners

12

-

-

-

267

14

440

733

Profit for the period

-

-

-

-

-

-

3,576

3,576

Foreign exchange on consolidation of subsidiaries

 

-

 

-

 

-

 

(161)

 

-

 

-

 

-

 

(161)

Total comprehensive income for the period

 

-

 

-

 

-

 

(161)

 

-

 

-

 

3,576

 

3,415

Balance at 31 October 2021

996

2,606

424

(76)

9,359

726

16,885

30,922

 

 

12 months to 30 April 2022 - audited

Share

capital

£'000

Merger

reserve

£'000

 

Merger relief reserve

£'000

Foreign

exchange

£'000

Share

premium

£'000

Share-based payment reserve

£'000

Retained

earnings

£'000

Total

£'000

Balance at 30 April 2021

 984

 2,606

 424

 85

 9,092

 714

 12,869

 26,774

Shares issued

 38

 -

 -

 -

 813

 -

 -

 851

Tax in respect to share options

 -

 -

 -

 -

 -

 -

 357

 357

Share-based payments transfer

 -

 -

 -

 -

 -

(707)

 707

 -

Share based payments

 -

 -

 -

 -

 -

 313

 -

 313

Transactions with owners

 38

 -

 -

 -

 813

(394)

 1,064

 1,521

Profit for the year

 -

 -

 -

 -

 -

 -

 7,543

 7,543

Foreign exchange on consolidation of subsidiaries

 -

 -

 -

(46)

 -

 -

 -

(46)

Total comprehensive income

 -

 -

 -

(46)

 -

 -

 7,543

 7,497

Balance at 30 April 2022

 1,022

 2,606

 424

 39

 9,905

 320

 21,476

 35,792

Notes to the interim financial statements

 

 

1. General information and basis of preparation

 

SDI Group plc (the "Company"), a public limited company, is the Group's ultimate parent. It is registered in England and Wales. The consolidated interim financial statements of the Company for the period ended 31 October 2022 comprise the Company and its subsidiaries (together referred to as the "Group").

 

The unaudited consolidated interim financial statements are for the six months ended 31 October 2022. These interim financial statements have been prepared using the recognition and measurement principles of International Accounting Standards in conformity with the requirements of the Companies Act 2006. The consolidated interim financial information has been prepared under the historical cost convention, as modified by the recognition of certain financial instruments at fair value. The consolidated interim financial statements are presented in British pounds (£), which is also the functional currency of the ultimate parent company.

 

The consolidated interim financial information was approved by the Board of Directors on 7 December 2022.

 

The financial information set out in this interim report does not constitute statutory accounts as defined in section 435 of the Companies Act 2006. The figures for the year ended 30 April 2022 have been extracted from the statutory financial statements of SDI Group plc which have been filed with the Registrar of Companies. The auditor's report on those financial statements was unqualified and did not contain a statement under section 498(2) or 498(3) of the Companies Act 2006. The financial information for the six months ended 31 October 2022 and for the six months ended 31 October 2021 has not been audited.

 

2. Principal accounting policies

The principal accounting policies adopted in the preparation of the condensed consolidated interim information are consistent with those followed in the preparation of the Group's financial statements for the year ended 30 April 2022.

The accounting policies have been applied consistently throughout the Group for the purposes of preparation of these interim financial statements.

 

3. Alternative Performance Measures

The Group uses Adjusted Operating Profit, Adjusted Profit Before Tax, Adjusted Diluted EPS and Net Operating Assets as supplemental measures of the Group's profitability and investment in business related assets, in addition to measures defined under IFRS. The Group considers these useful due to the exclusion of specific items that are considered to hinder comparison of underlying profitability and investments of the Group's segments and businesses and is aware that shareholders use these measures to evaluate performance over time. The adjusting items for the alternative measures of profit are either recurring but non-cash charges (share-based payments and amortisation of acquired intangible assets) or exceptional items (reorganisation costs and acquisition costs).

 

The following table is included to define the term Adjusted Operating Profit:

 

 

 

 

6 months to

31 October

2022

Unaudited

£'000

6 months to

31 October

2021

Unaudited

£'000

12 months to

30 April

2022

Audited

£'000

 

 

 

Operating Profit (as reported)

5,623

5,207

10,179

 

 

Adjusting items (all costs):

 

 

Non-underlying items

 

 

Share based payments

140

159

313

Amortisation of acquired intangible assets

823

465

1,115

Exceptional items

 

 

Reorganisation costs

-

-

125

Acquisition costs

267

-

341

Total adjusting items within Operating Profit

1,230

624

1,894

 

 

Adjusted Operating Profit

6,853

5,831

12,073

 

Adjusted Profit Before Tax is defined as follows:

 

 

6 months to

31 October

2022

Unaudited

£'000

6 months to

31 October

2021

Unaudited

£'000

12 months to

30 April

2022

Audited

£'000

 

 

 

 

Profit Before Tax (as reported)

5,305

5,102

9,884

 

 

Adjusting items (as above)

1,230

624

1,894

 

 

Adjusted Profit Before Tax

6,535

5,726

11,778

 

3. Alternative Performance Measures (continued)

 

Adjusted EPS is defined as follows:

 

 

 

6 months to

31 October

2022

Unaudited

£'000

6 months to

31 October

2021

Unaudited

£'000

12 months to

30 April

2022

Audited

£'000

 

 

 

 

Profit for the Period (as reported)

4,244

3,576

7,543

 

 

Adjusting items (as above)

1,230

624

1,894

Less: taxation on adjusting items calculated at the UK statutory rate

 

(234)

 

(119)

 

(360)

Adjusted profit for the period

5,240

4,081

9,077

 

 

Divided by diluted weighted average number of shares in issue (Note 5)

104,411,856

104,138,768

104,259,085

 

 

 

 

Adjusted Diluted EPS

5.02p

3.92p

8.71p

 

 

Net Operating Assets is defined as follows:

 

 

 

 

31 October

2022

Unaudited

£'000

31 October

2021

Unaudited

£'000

30 April

2022

Audited

£'000

 

 

 

Net Assets

40,656

30,922

35,792

 

 

Deferred tax asset

1,547

1,660

1,586

Corporation tax asset

569

486

137

Cash and cash equivalents

3,619

3,513

5,106

Borrowings (current and non-current)

(26,106)

(4,834)

(11,435)

Deferred consideration

(2,460)

-

(3,305)

Deferred tax liability

(5,795)

(2,993)

(4,417)

Current tax payable

(1,889)

(1,165)

(1,027)

Total adjusting items within Net Assets

(30,515)

(3,333)

(13,355)

 

 

Net Operating Assets

71,171

34,255

49,147

 

4. Segmental analysis

 

 

 

6 months to

31 October

2022

Unaudited

 

£'000

6 months to

31 October

2021

Unaudited

 

£'000

12 months to

30 April

2022

Audited

 

£'000

Revenues

 

 

Digital Imaging

12,529

11,373

21,492

Sensors & Control

19,191

13,292

28,164

Group

31,720

24,665

49,656

 

 

Adjusted operating profit

 

 

Digital Imaging

4,692

4,253

8,502

Sensors & Control

2,914

2,505

5,188

Other

(753)

(927)

(1,617)

Group

6,853

5,831

12,073

 

 

Amortisation of acquired intangible assets

 

 

Digital Imaging

(92)

(92)

(175)

Sensors & Control

(735)

(377)

(940)

Group

(827)

(469)

(1,115)

 

Adjusted Operating Profit has been defined in Note 3.

 

Analysis of amortisation of acquired intangible assets has been included separately as the Group considers it to be an important component of profit which is directly attributable to the reported segments.

 

The Other category includes costs which cannot be allocated to the other segments and consists principally of Group head office costs.

4. Segmental analysis (continued)

 

 

 

 

31 October

2022

Unaudited

 

£'000

31 October

2021

Unaudited

 

£'000

30 April

2022

Audited

 

£'000

Operating Assets excluding acquired intangible assets

 

 

Digital Imaging

8,191

9,612

7,501

Sensors & Control

29,868

9,757

19,045

Other

676

(257)

247

Group

38,735

19,112

26,793

 

 

Acquired intangible assets

 

 

Digital Imaging

4,932

5,107

5,019

Sensors & Control

41,675

19,978

30,282

Group

46,607

25,085

35,301

 

 

Operating Liabilities

 

 

Digital Imaging

(3,133)

(4,650)

(4,905)

Sensors & Control

(10,383)

(4,192)

(7,075)

Other

(655)

(1,101)

(968)

Group

(14,171)

(9,943)

(12,948)

 

 

Net Operating Assets

 

 

Digital Imaging

9,989

10,069

7,616

Sensors & Control

61,161

25,543

42,251

Other

21

(1,357)

(720)

Group

71,171

34,255

49,147

 

Net operating assets has been defined in Note 3.

5. Earnings per share

The calculation of the basic earnings per share is based on the profits attributable to the shareholders of SDI Group plc divided by the weighted average number of shares in issue during the period. All profit per share calculations relate to continuing operations of the Group.

 

 

 

 

Profit

 attributable to

shareholders

£'000

Weighted

average

number of

shares

Earnings

per share

amount in

pence

Basic earnings per share:

 

 

 

Period ended 31 October 2022

4,244

102,215,980

4.15

Period ended 31 October 2021

3,576

99,120,392

3.61

Year ended 30 April 2022

7,543

100,122,394

7,53

 

Dilutive effect of share options:

 

Period ended 31 October 2022

2,195,876

 

Period ended 31 October 2021

5,018,376

 

Year ended 30 April 2022

4,136,692

 

 

Diluted earnings per share:

 

 

 

Period ended 31 October 2022

4,244

104,411,856

4.06

Period ended 31 October 2021

3,576

104,138,768

3.43

Year ended 30 April 2022

7,543

104,259,085

7.23

 

 

 

6. Borrowings

31 October

2022

£'000

31 October

2021

£'000

30 April

2022

£'000

Within one year:

 

Bank finance

-

1,371

-

Leases

803

498

779

803

1,869

779

After one year and within five years:

 

Bank finance

19,000

1,029

4,000

Leases

5,476

1,065

6,656

24,476

2,094

10,656

After more than five years:

 

Leases

827

871

-

 

Total borrowings

26,106

4,834

11,435

 

Bank finance relates to amounts drawn down under the Group's bank facility with HSBC Bank plc, which is secured against all assets of the Group. On 1 November 2021 the Group renewed and expanded its committed loan facility with HSBC to £20m, with a further accordion option of an additional £10m (at the discretion of HSBC), and with repayment date of November 2024 extendable for two further years. The revolving facility is available for general use. The facility has covenants relating to leverage (net debt to EBITDA) and interest coverage. At 31 October 2022, the Group had £1m of headroom within its £20m committed loan facility with HSBC. On 30 November 2022, the Group reached agreement with HSBC to exercise £5m of the accordion option, which increased the committed loan facility from £20m to £25m, hence increasing the available head room to £6m. The balance of the accordion option (£5m) remains available to the Group (at the discretion of HSBC) for future exercise.

7. Acquisitions

On 29 July 2022, the Group acquired 100% of the share capital of LTE Scientific Systems Limited ("LTE"), for a total consideration of £5.5m, which included freehold ownership of its manufacturing facility, valued at approximately £1.7m. LTE specialises in the design, manufacture and servicing of sterilizers, decontamination and thermal processing equipment, used in the life science and medical market sectors. For the year ended 31 December 2021, LTE achieved revenues of £6.4m and profit before tax of £0.4m. The acquisition is expected to be earnings enhancing in the current financial year.

On 21 October 2022, the Group acquired 100% of the share capital of Fraser Anti-Static Techniques Limited ("Fraser"), for a total consideration of £16.9m, of which £15.4m was paid before the period end and £1.5m is due to be paid over the second half of the financial year. Approximately £1.0m of the deferred consideration is based on net assets delivered at completion. The total consideration includes freehold ownership of three of Fraser's manufacturing sites, valued at approximately £1.8m. Fraser is a leading UK manufacturer of anti-static products which eliminate, clean, generate or measure static electricity in a variety of industries including plastics, packaging, printing, food processing, medical and pharma amongst others. For the year ended 30 November 2021, Fraser achieved revenues of £7.4m and profit before tax of £1.9m. The acquisition is expected to be earnings enhancing in the current financial year.

 

During the previous financial year, the Group completed the acquisition of Safelab Systems for which contingent consideration of £2.4m was outstanding at 30 April 2022. This amount was settled in cash in the current period.

 

8. Taxation

The Group has estimated an effective tax rate of 20% for the year and has applied this rate to the profit before tax for the period. A gain of £117k (H1 FY22: £295k) resulting from changes to the estimate of future tax relief from share option exercises, including the estimated effect of changes in the tax rate, has been booked directly to equity.

 

 

 

 

SDl Group plc

Beacon HouseNuffield RoadCambridgeCB4 1TFUK

Telephone: +44 (0)1223 727144Fax: +44 (0)1223 727101

Email: info@sdigroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR UPGQGPUPPGMQ
Date   Source Headline
3rd Apr 20242:15 pmRNSExercise of Share Options and Total Voting Rights
18th Mar 202412:49 pmRNSHolding(s) in Company
18th Mar 20247:00 amRNSDirector/PDMR Shareholding
8th Mar 20243:15 pmRNSHolding(s) in Company
26th Feb 20247:00 amRNSLong Term Incentive Plan Awards
23rd Feb 202411:00 amRNSHolding(s) in Company
21st Feb 20246:00 pmRNSDirector/PDMR Shareholding
20th Feb 20247:00 amRNSHolding(s) in Company
13th Feb 202411:14 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSDirectorate Change – Appointment of New CEO
8th Dec 20233:45 pmRNSHolding(s) in Company
8th Dec 20232:30 pmRNSHolding(s) in Company
7th Dec 20231:15 pmRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSInterim Results
4th Dec 20237:00 amRNSNotice of Results and Investor Presentation
7th Nov 20234:10 pmRNSDirector/PDMR Shareholding
7th Nov 20233:50 pmRNSDirector/PDMR Shareholding and TVR - Replacement
7th Nov 20237:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
6th Nov 20237:00 amRNSAcquisition of Peak Sensors
31st Oct 20234:20 pmRNSHolding(s) in Company
26th Oct 20235:45 pmRNSHolding(s) in Company
29th Sep 202311:30 amRNSResult of AGM
29th Sep 20237:00 amRNSAGM Trading Update
24th Aug 20237:00 amRNSBoard Appointment
8th Aug 20237:00 amRNSFinal Results
2nd Aug 20237:00 amRNSNotice of Results and Investor Presentation
26th May 20231:40 pmRNSHolding(s) in Company
16th May 20232:55 pmRNSHolding(s) in Company
11th May 202311:50 amRNSDirector Dealing
11th May 20237:00 amRNSTrading Update
19th Apr 20231:00 pmRNSDirector/PDMR Shareholding and TVR
12th Apr 20235:15 pmRNSDirector/PDMR Shareholding
31st Mar 20233:45 pmRNSDirector Dealing
15th Mar 202312:00 pmRNSHolding(s) in Company
15th Feb 20235:30 pmRNSHolding(s) in Company
13th Feb 20233:55 pmRNSHolding(s) in Company
3rd Feb 20232:00 pmRNSExercise of Options and Total Voting Rights
1st Feb 202310:15 amRNSHolding(s) in Company
1st Feb 20237:00 amRNSBoard Appointment
5th Jan 202310:00 amRNSExercise of Options and Total Voting Rights
14th Dec 20224:00 pmRNSExercise of Options and Total Voting Rights
7th Dec 20227:00 amRNSInterim Results
7th Nov 20227:00 amRNSInvestor Presentation
3rd Nov 20227:00 amRNSNotice of Results
27th Oct 20223:55 pmRNSDirector Dealings, Exercise of Options and TVR
26th Oct 20227:00 amRNSLong Term Incentive Plan Awards
24th Oct 20227:00 amRNSAcquisition of Fraser Anti-Static Techniques Ltd
21st Sep 20224:15 pmRNSResult of AGM and Board Appointment
21st Sep 20227:00 amRNSAGM Trading Update
24th Aug 20227:00 amRNSPosting of Annual Report and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.